27760426|t|Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation -Engendered Toxicity
27760426|a|Alzheimer's disease (AD) is the most abundant tauopathy and is characterized by Aβ -derived plaques and tau -derived tangles, resulting from the unfolding of the corresponding monomeric subunits into ordered β-sheet oligomers and fibrils. Intervening in the toxic aggregation process is a promising therapeutic approach, but, to date, a disease -modifying therapy is neither available for AD nor for other tauopathies. Along these lines, we have previously demonstrated that a small naphthoquinone-tryptophan hybrid, termed NQTrp, is an effective modulator of tauopathy in vitro and in vivo. However, NQTrp is difficult to synthesize and is not very stable. Therefore, we tested whether a more stable and easier-to-synthesize modified version of NQTrp, containing a Cl ion, namely Cl-NQTrp, is also an effective inhibitor of tau aggregation in vitro and in vivo. Cl-NQTrp was previously shown to efficiently inhibit the aggregation of various amyloidogenic proteins and peptides. We demonstrate that Cl-NQTrp inhibits the in vitro assembly of PHF6, the aggregation -prone fragment of tau, and alleviates tauopathy symptoms in a transgenic Drosophila model through the inhibition of tau aggregation -engendered toxicity. These results suggest that Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau.
27760426	0	8	Cl-NQTrp	T116,T121	C3501592
27760426	20	29	Tauopathy	T047	C0949664
27760426	30	38	Symptoms	T184	C1457887
27760426	44	58	Model Organism	T050	C0012644
27760426	71	81	Inhibition	T052	C3463820
27760426	85	88	Tau	T116,T123	C0085401
27760426	89	100	Aggregation	T044	C3850147
27760426	113	121	Toxicity	T037	C0600688
27760426	122	141	Alzheimer's disease	T047	C0002395
27760426	143	145	AD	T047	C0002395
27760426	168	177	tauopathy	T047	C0949664
27760426	202	204	Aβ	T116	C3484390
27760426	214	221	plaques	T020	C0333463
27760426	226	229	tau	T116,T123	C0085401
27760426	239	246	tangles	T049	C0085400
27760426	267	276	unfolding	T043	C1655065
27760426	298	316	monomeric subunits	T116	C0599220
27760426	330	337	β-sheet	T082	C0162806
27760426	338	347	oligomers	T087	C0599219
27760426	352	359	fibrils	T026	C0225328
27760426	361	372	Intervening	T061	C0184661
27760426	386	397	aggregation	T044	C3850147
27760426	421	441	therapeutic approach	T061	C0087111
27760426	459	466	disease	T047	C0012634
27760426	478	485	therapy	T061	C0087111
27760426	511	513	AD	T047	C0002395
27760426	528	539	tauopathies	T047	C0949664
27760426	605	637	naphthoquinone-tryptophan hybrid	T116,T123	C3711678
27760426	646	651	NQTrp	T116,T123	C3711678
27760426	682	691	tauopathy	T047	C0949664
27760426	692	700	in vitro	T080	C1533691
27760426	705	712	in vivo	T082	C1515655
27760426	723	728	NQTrp	T116,T123	C3711678
27760426	763	778	not very stable	T033	C0443343
27760426	816	822	stable	T080	C0205360
27760426	868	873	NQTrp	T116,T123	C3711678
27760426	888	894	Cl ion	T196	C0596019
27760426	903	911	Cl-NQTrp	T116,T121	C3501592
27760426	934	943	inhibitor	T080	C1999216
27760426	947	950	tau	T116,T123	C0085401
27760426	951	962	aggregation	T044	C3850147
27760426	963	971	in vitro	T080	C1533691
27760426	976	983	in vivo	T082	C1515655
27760426	985	993	Cl-NQTrp	T116,T121	C3501592
27760426	1030	1037	inhibit	T052	C3463820
27760426	1042	1053	aggregation	T044	C3850147
27760426	1065	1087	amyloidogenic proteins	T116,T123	C1456454
27760426	1092	1100	peptides	T116	C0030956
27760426	1122	1130	Cl-NQTrp	T116,T121	C3501592
27760426	1131	1139	inhibits	T052	C3463820
27760426	1144	1152	in vitro	T080	C1533691
27760426	1153	1161	assembly	T044	C0872376
27760426	1165	1169	PHF6	T116,T130	C1335533
27760426	1175	1186	aggregation	T044	C3850147
27760426	1194	1202	fragment	T116,T130	C1335533
27760426	1206	1209	tau	T116,T123	C0085401
27760426	1226	1235	tauopathy	T047	C0949664
27760426	1236	1244	symptoms	T184	C1457887
27760426	1250	1260	transgenic	T008	C0003069
27760426	1261	1271	Drosophila	T204	C0013138
27760426	1272	1277	model	T050	C1519606
27760426	1290	1300	inhibition	T052	C3463820
27760426	1304	1307	tau	T116,T123	C0085401
27760426	1308	1319	aggregation	T044	C3850147
27760426	1332	1340	toxicity	T037	C0600688
27760426	1369	1377	Cl-NQTrp	T116,T121	C3501592
27760426	1406	1417	therapeutic	T169	C0302350
27760426	1422	1424	AD	T047	C0002395
27760426	1442	1453	aggregation	T044	C3850147
27760426	1462	1464	Aβ	T116	C3484390
27760426	1469	1472	tau	T116,T123	C0085401